Abstract:. China has approved the first CAR T-cell therapy that targets solid tumors, satricabtagene autoleucel (satri-cel), for patients with claudin 18.2–positive, HER2-negative gastric or ...
AbstractBreast cancer is the most commonly diagnosed malignancy and a leading cause of cancer-related mortality. Hormone receptor–positive (HR+) tumors represent the most prevalent metastatic subtype, ...
Abstract:. For people with localized, high-risk prostate cancer, treatment with 6 months of apalutamide and androgen deprivation therapy (ADT) both before and after surgery reduces the risk of ...
Abstract:. In the phase I inMMyCAR study of the in vivo chimeric antigen receptor (CAR) T-cell therapy KLN-1010, all 18 patients with multiple myeloma responded. None of the evaluable patients had ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
You do not currently have access to this content.
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
DCx Biotherapeutics, Saint-Laurent, Quebec, Canada.
Search for other works by this author on: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results